

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Maria Palasis

Group Art Unit: 3763

Application No.: 09/760,807

Examiner: Loan H. Thanh

Filed: January 17, 2001

Docket No.: 12013/58101

For: THERAUPEUTIC DELIVERY BALLOON

RECEIVED

DEC 0 9 2003

TECHNOLOGY CENTER R3700

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office Washington, D.C. 20231

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449 and the enclosed PCT Search Report. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable.

- 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- 1 2. This Information Disclosure Statement is being filed with a Request for Continued Examination (RCE). No certification or fee is required.
- 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

	patent	a. I hereby certify that each item of information contained in this nation Disclosure Statement was cited in a communication from a foreign office in a counterpart foreign application not more than three months prior filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	in a co	b. I hereby certify that no item of information in this Information sure Statement was cited in a communication from a foreign patent office ounterpart foreign application or, to my knowledge after making reasonable y, was known to any individual designated in 37 CFR §1.56(c) more than months prior to the filing of this Information Disclosure Statement. 37 CFR (e)(2).
		c. Please debit Deposit Account No. 11-0600 in the amount of 00 in payment of the fee under 37 CFR §1.17(p) to ensure consideration of sclosed information. Two duplicate copies of this paper are attached.
of Allo the Inf <u>11-060</u> §1.17(wance formation oo_in th (i)(1) to	This Information Disclosure Statement is being filed more than three the U.S. filing date and after the mailing date of a Final Rejection or Notice, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that on Disclosure Statement be considered. Please debit Deposit Account No. he amount of \$130.00 in payment of the petition fee under 37 CFR ensure consideration of the disclosed information. Two duplicate copies are attached.
	patent	a. I hereby certify that each item of information contained in this nation Disclosure Statement was cited in a communication from a foreign office in a counterpart foreign application not more than three months prior filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
	in a co	b. I hereby certify that no item of information in this Information sure Statement was cited in a communication from a foreign patent office ounterpart foreign application or, to my knowledge after making reasonable y, was known to any individual designated in 37 CFR §1.56(c) more than months prior to the filing of this Information Disclosure Statement. 37 CFR (e)(2).
	5. nt spec	Relevance of the non-English language reference(s) is discussed in the ification.
⊠ Englis inform	h langւ	The reference(s) was/were cited in a counterpart foreign application. An uage version of the foreign search report is attached for the Examiner's
☐ refere		A concise explanation of the relevance of the non-English language appears in the Appendix attached hereto.
☐ No		The Examiner's attention is directed to co-pending U.S. Patent Application , filed, which is directed to related technical subject matter. The

identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination of the present application.

attac ident secre pater	hed Ap ificatior ecy as t nt. The	pendix, which an of those U.S. P o those applicat	re directed to rela Patent Applicatior ions now or upor spectfully request	es of related applications, identified in ated technical subject matter. The as is not to be construed as a waiver a issuance of the present applications ed to consider the cited applications	of as a
appli	cation I under 3	No,	filed	d by or submitted to the Office in pare , which is relied upon for an earlied these references are not attached. 3	r filing
	11. hed he		age Abstracts of	the non-English language references	are
	12. 0	ther.			
				Respectfully submitted,	
		v		KENYON & KENYON	Λ

Douglas E. Ringel

Registration No. 34,416



The stamp of a patent Office may be taken as acknowledging the date stamped, of

receipt, on D.104

INVENTOR(S): Maria Palasis

SERIAL NO.: 09

09/760,807

FILED: January 17, 2001

TITLE: THERAPEUTIC DELIVERY BALLOON

The PTO is authorized to charge \$240.00 fee regarding this filing to Deposit Account No. 11-0600.

PAPERS FILED:

1. INFORMATION DISCLOSURE STATEMENT W/PTO FORM 1449,

(2) TWO REFERENCES AND INTERNATIONAL SERBETH REPORT.

APR 0 4 2003

Douglas E. Ringel/DLW/vjw

12013/58101

April 4, 2003

RECEIVED
DEC 0 9 2003
TECHNOLOGY CENTER R3700

92/23/2004 STHOMAS 00000001 110600 09760807

01 FC:1806

360.00 DA